2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Suspended
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Multiple Myeloma
2
Leukemia, Myeloid, Acute
2
Epstein-Barr Virus Infections
2
Cytomegalovirus Infections
2
Colorectal Neoplasms
2
Adenoviridae Infections
2
Vulvar Neoplasms
1
Vulvar Diseases
1
Uterine Cervical Dysplasia
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Recurrence
1
Rectal Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Peritoneal Neoplasms
1
Papillomavirus Infections
1
Ovarian Neoplasms
1
Ovarian Diseases
1
Neoplasms, Glandular and Epithelial
1
Neoplasms
1
Neoplasm Metastasis
1
Nasopharyngeal Carcinoma
1
Myelodysplastic Syndromes
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Immunologic Deficiency Syndromes
1
Hodgkin Disease
1
Interventions
pembrolizumab
185
Gemcitabine
170
Paclitaxel
152
Carboplatin
137
Bevacizumab
128
Surveys and Questionnaires
118
Cisplatin
115
Docetaxel
114
Blood Specimen Collection
110
Cyclophosphamide
109
Exercise
108
Nivolumab
98
Fluorouracil
90
Capecitabine
86
Dexamethasone
81
Radiotherapy
80
Irinotecan
74
Standard of Care
69
Pemetrexed
68
Oxaliplatin
68
Leucovorin
64
Drug Therapy
64
Cetuximab
60
Erlotinib Hydrochloride
56
Sorafenib
53
atezolizumab
52
Ipilimumab
51
Doxorubicin
50
trametinib
47
Interviews as Topic
47
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
Cell Count
×
Clear all
NCT05887882
2026-04-24
PNOC028
University of California, San Francisco
Phase 1
Suspended
24 enrolled